ª«·~¼Æ¾Ú®t ¬üªÑ¥ý¶^«áÃ
Valeant¦¨¥[ªÑ¤W¤É°Ê¤O
¡i©ú³ø±M°T¡j¬ü°ê¤G¤âª«·~¥æ§ë¦^¸¨¡A¥O¬üªÑ¦¬q¤U¶^¡A¦ý¤§«á¹q°T»P°·±dÅ@²zªÑ¤W¤É¡A©è®ø¯à·½¤Îª«®ÆªÑ¤U¶^¡A¥O¬üªÑ¤T¤j«ü¼Æ¥þ±¤W¤É¡A¨ä¤¤¹D«ü§ó¿ý±o³sÄò²Ä¤CÓ¥æ©ö¤é¤W¤É¡A¨£2015¦~10¤ë¥H¨Ó³Ìªø¤W¤É©P´Á¡F¥[ªÑ¥ç¥ý¶^«á¤É¡A¤É´T¸û¬üªÑ¤j¡A¥Dn¬O¨ü´fValeant Pharmaceutical(¥N¸¹VRX)ªÑ»ù¦V¤W©Ò±a°Ê¡C
¹D«ü¦¬³ø17,623.87¡A¤W¤É21.57¡F¼Ð´¶500«ü¼Æ¦¬³ø2.051.6¡A¤W¤É2.02¡F¯Ç«ü¦¬³ø4,808.87¡A¤W¤É13.22¡F¥[°ê¦h«ü¦¬³ø13,561.09¡A¤W¤É64.02¡C
¬ü°ê¥þ°ê©Ð¦a²£¸g¬ö¨ó·|¤½¥¬2¤ë¥÷¤G¤âª«·~¦¨¥æ¶q¤U¶^7.1¢H¡A¬O¹L¥h3Ó¤ë¥H¨Óº¦¸¿ý±o¤U¶^¡F¦Ó¥[°êÃļtValeant¦]¦æ¬FÁ`µôMichael PearsonÂ÷¾¡A®ø®§¨ë¿EªÑ»ù¤W¤É8.5¢H¡A±a°Ê¥[°ê°·±dÅ@²zªÑ¦V¤W4.27¢H¡C